Israel's Ornim raises $20M for noninvasive continuous blood-flow monitor

Ornim, maker of a noninvasive patient blood flow monitoring system, closed an initial $20 million Series C round. The funding will help the company commercialize its product in Asia, as well as in the U.S.

The FDA-cleared c-FLOW monitoring system is the company’s lead product. It provides real-time, continuous monitoring of patients’ perfusion, or blood flow, measurements to the brain and other tissues. The device is based on Ornim’s UTLight technology, which uses near-infrared light and ultrasound to nonivasively measure changes in cerebral blood flow and blood flow to muscle tissues.

Tracking cerebral blood flow measurements is a major factor in surgeries that require general anesthesia as well as in treating patients at risk of cerebral blood flow changes, such as stroke, cerebral edema and traumatic brain injury. By continuously providing measurements, c-FLOW can enable clinicians to plan interventions early enough to minimize or ward off brain injury, thus improving outcomes and reducing costs.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

LongTec HongTao China Ventures led the round, while existing investors OrbiMed and GE Ventures also participated. The company anticipates an additional investment of up to $10 million, according to the statement. OrbiMed previously led a $10 million financing round in 2014.

“LongTec's extensive expertise in developing and commercializing medical technologies in China and throughout Asia will greatly accelerate our current efforts in expanding our global market opportunity,” said Ornim CEO Israel Schreiber. While the company expands its U.S. presence, it is also seeking a China FDA nod for the c-FLOW system. Schreiber expects to hit the Chinese market in 2017 following clearance.

- here's the statement

Related Articles:
Researchers study noninvasive device to monitor brain blood flow
Cheetah Medical's blood flow monitoring tech draws $9M in financing

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.